While artificial intelligence and semiconductor stocks continue to dominate headlines, a little-known genetic testing company has been staging a stealth rally that puts even Nvidia to shame. Shares of Natera (NTRA) have climbed more than 72% over the past 12 months — triple the roughly 24% return posted by Nvidia over the same stretch. Even more striking: the company, with a market cap just above $30 billion, has become the single largest holding in the family office of billionaire investor Stanley Druckenmiller.
According to the latest quarterly filing from Duquesne Family Office, Natera accounted for 18.1% of the portfolio as of the end of the first quarter of 2026, with the stake valued at slightly less than $613 million. While regulatory filings do not require an explanation of the investment rationale, the sheer scale of Druckenmiller’s position suggests a clear conviction: the genetic testing market is only getting started. Data from Grand View Research pegs the global genetic testing market at just $11.7 billion in 2024, with expectations it will reach $39.3 billion by 2030. The cancer diagnostics market is even larger, projected to grow from $119.8 billion in 2025 to $191.1 billion by 2033.
Natera specializes in non-invasive, cell-free DNA testing across oncology, organ health, women’s health, and rare diseases. Oncology testing is the company’s most powerful growth engine. In 2025, processed oncology tests jumped 51.6% to more than 800,000, up from over 528,000 in 2024. That momentum carried into 2026, with first-quarter oncology test volumes again rising more than 50% year over year. The company hit another milestone in June when its Signatera test became the first molecular residual disease test approved in Japan for patients with colorectal cancer, with a commercial launch expected before the end of 2026 — a move that opens a significant new overseas growth avenue.
Hard numbers have underpinned the stock’s climb. Full-year 2025 revenue reached $2.3 billion, up 35.9% from 2024, driven by 3.5 million total tests processed, a 15% increase. The momentum has only strengthened in 2026: in the first quarter, Natera processed more than one million tests in a single quarter for the first time, reported revenue of $697 million — a 39% year-over-year jump — and raised the midpoint of its full-year revenue guidance by $120 million. Wall Street analysts project full-year revenue of $2.8 billion for 2026, rising to $3.3 billion in 2027. According to Precedence Research, the global genetic testing market is forecast to grow at a compound annual rate of more than 11% through 2035, by which point it could exceed $70 billion, leaving Natera well-positioned to capture a substantial share.
However, heady growth hasn’t yet translated into profits. Natera’s net loss widened from $190.4 million in 2024 to $208.2 million in 2025, while research and development spending surged from $129.1 million in the first quarter of 2025 to $210.7 million a year later — a clear sign the company is sparing no expense to widen its competitive moat. The profit outlook is far from settled: while the consensus forecast calls for earnings of $1.43 per share in fiscal 2028, individual analyst estimates range from a loss of $1.32 a share to a profit of $5.03, reflecting enormous disagreement about how — and when — the bottom line will turn.
Nineteen of the 22 analysts covering Natera rate the stock a buy, and Druckenmiller himself appears entirely at ease with the risks. But the patience and risk tolerance of a billionaire are not something the average investor can afford to replicate. Whether Druckenmiller’s outsized wager proves to be the next ten-bagger or an expensive bet on a still-unprofitable growth narrative remains a question only time can answer.
